Lonza cites biotech funding slowdown as it lowers sales outlook for the year
Contract manufacturer Lonza tempered its sales outlook for the rest of the year due in part to lower-than-expected growth in the services it provides to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
